IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapyPositive ProSense® results were reported through 33 peer-reviewed journals and medical conferences during 2024Conference call to be held today at 10:00 am Eastern TimeCAESAREA, Israel, March 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alter ...